Traws Pharma, Inc. (TRAW)

In the past six months, Traws Pharma's stock has experienced volatility and been impacted by several key events. On February 19, 2026, the stock saw a significant decline after the company completed the analysis of its Ratutrelvir clinical study. On January 26, 2026, the stock price increased after the company announced the completion of enrollment for the Ratutrelvir clinical study. On January 13, 2026, the stock price increased after Traws Pharma filed a Tivoxavir Marboxil Investigational New Drug Application. On December 17, 2025, the stock experienced a substantial drop. On November 13, 2025, the stock declined following the report of its Q3 2025 results and business highlights. On October 30, 2025, the stock saw a change. On March 31, 2026, Traws Pharma filed a notification of late filing for its Annual Report on Form 10-K. TRAW's share price has been volatile over the past three months compared to the US market, and its weekly volatility has been stable over the past year, remaining higher than 75% of US stocks.

As a clinical-stage biopharmaceutical company, Traws Pharma, Inc. does not have traditional demand seasonality for its products and services. However, there is seasonality observed in the company's stock performance. Historically, June has shown the highest probability of positive returns for TRAW stock, while March may not be an ideal month for investment.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for critical threats to human health, primarily in respiratory viral diseases and cancer. The company's pipeline includes several investigational oral small-molecule antiviral agents and oncology therapeutics. Its major product candidates are Tivoxavir marboxil, Ratutrelvir (TRX01), Narazaciclib, and Rigosertib.

Traws Pharma, Inc. is headquartered in Newtown, Pennsylvania, United States. The company has plans for a Phase 2 study for Tivoxavir marboxil in Australia and select Southeast Asian countries, indicating a potential future international reach for its clinical trials.

Traws Pharma, Inc. positions itself as a company dedicated to developing novel therapies for critical threats to human health. The company's reputation has been shaped by its progress in clinical trials and regulatory interactions. However, the recent delay in filing its Annual Report on Form 10-K could raise concerns regarding financial stability and operational execution, potentially impacting its reputation among investors.

Traws Pharma, Inc. has a notable institutional ownership presence. As of March 31, 2026, approximately 7.95% of Traws Pharma's stock is owned by institutional investors. Major institutional owners include Adage Capital Partners Gp, L.l.c., Squadron Capital Management LLC, and others.